Press Conference: Launching World's First Antimicrobial Resistance Benchmark a0W0X00000AfRVSUA3

TL;DR

The World Economic Forum hosts a press conference to discuss the results of the first-ever antimicrobial resistance benchmark, highlighting the actions taken by pharmaceutical companies to tackle drug resistance.

Transcript

good afternoon and welcome to this press conference from the 48th annual meeting of the World Economic Forum here in Davos thank you for those of you in the room who made it through the snow to be with us and much easier for those of you who are on our livestream but still thank you for watching this press conference is dedicated to the launch of t... Read More

Key Insights

• 🌐 Antimicrobial resistance is a global threat that requires immediate action from governments, pharmaceutical companies, and other stakeholders.
• 🥹 The benchmark serves as a tool to hold pharmaceutical companies accountable for their efforts in addressing drug resistance.
• 🥺 GSK and Johnson & Johnson are recognized as leaders among pharmaceutical companies, while Mailand Supply and Fresenius Kabi lead among generic companies, and Entasis leads in the biotechnology industry.
• 👶 The development of new antibiotics and vaccines is crucial to combatting antimicrobial resistance.
• ❓ Collaboration and collaboration between academia, industry, and governments is essential to address the challenge effectively.
• 🖐️ Philanthropy plays a critical role in funding research and serving as a bridge between society and the pharmaceutical industry.

Questions & Answers

Q: What was the motivation behind creating the antimicrobial resistance benchmark?

The benchmark was created to clarify the role of the pharmaceutical industry in tackling antimicrobial resistance and to encourage responsible actions and behavior from companies. It aims to assess their efforts in addressing this global threat.

Q: What were the key findings of the benchmark?

The benchmark found that there is more evidence of action against drug resistance than expected. GSK and Johnson & Johnson showed the most evidence of activity, while Mailand Supply and Fresenius Kabi led the way among generic companies. In terms of research and development, more than half of the pipeline targets tough pathogens, but there is still a need for more novel antibiotics.

Q: How are companies balancing the need for accessibility and responsible use of antibiotics?

Companies are taking measures to ensure that antibiotics are accessible while also being used sparingly. Some companies have changed the way they incentivize sales staff, focusing on technical knowledge instead of sales volume to reduce the overselling of antibiotics. They are also working on ensuring responsible marketing and promotion of these products.

Q: How does antimicrobial resistance affect people in poorer countries?

People in poorer countries face higher levels of resistance and have less access to antibiotics when needed. This leads to higher morbidity and mortality rates due to infectious diseases. It is crucial for multi-stakeholders, including governments and pharmaceutical companies, to take action to address this issue.

Summary & Key Takeaways

• The antimicrobial resistance benchmark is an independent analysis of pharmaceutical companies' efforts to slow the emergence of drug resistance.

• The benchmark evaluates companies based on their development of new medicines and vaccines, responsible manufacturing practices, and careful marketing and promotion of antibiotics.

• GSK and Johnson & Johnson are recognized as leaders among pharmaceutical companies, while Mailand Supply and Fresenius Kabi lead among generic companies, and Entasis leads in the biotechnology industry.